Pycnogenol is one of the most important, useful and researched dietary supplements. I first reported on Pycnogenol in this column in 1991 and have gone on to write six books on Pycnogenol (1–7). Scientists continue to expand the pool of published scientific research about this unique blend of bioflavonoid-related nutrients extracted from a specific plant species (Pinus maritime, the Maritime Pine that grows exclusively along the coast of southwest France) by a patented process that concentrates specific antioxidant and anti-inflammatory nutrients. Therefore, it is important to keep readers abreast of the extensive ongoing research on Pycnogenol.
In September, consumers and the dietary supplement industry achieved a major victory in the pursuit of good health. On September 28, 2010, the U.S. Food and Drug Administration (FDA) and a coalition of health practitioners, scientists and manufacturers, including the Alliance for Natural Health (ANH), agreed on the wording for qualified health claims for selenium against various forms of cancer.
The U.S. Food and Drug Administration (FDA) just agreed to new Qualified Health Claims for selenium. The law firm of Emord & Associates announced on September 28 that a partial settlement with FDA has been achieved following the decision of the U.S. District Court for the District of Columbia in ANH v. Sebelius.
Do all omega-3 fatty acids provide heart benefits? Does the ratio of EPA to DHA matter? Is EPA good for the heart while DHA is good for the brain? Does it matter if EPA and DHA are present as free fatty acids, triglycerides or ethyl esters? Several misconceptions have arisen over the years and some readers may be surprised at the answers to these questions.
Last month, we chatted with Dr. Jørn Dyerberg about his major health discovery of omega-3 fatty acids in human health. While that part of the interview with Dr. Dyerberg was in press, another major confirming study was published that should be noted...
We have discussed the importance of the “advanced” carnitine called GPLC (GlycoCarn, from Sigma-tau HealthScience, Inc.) in previous columns with both cardiologist Stephen Sinatra, M.D., and exercise physiologist, Richard J. Bloomer, Ph.D.